Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
BAX's Cash to Debt is ranked higher than
51% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. BAX: 0.22 )
BAX' s 10-Year Cash to Debt Range
Min: 0.09   Max: 0.92
Current: 0.22

0.09
0.92
Equity to Asset 0.33
BAX's Equity to Asset is ranked higher than
51% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. BAX: 0.33 )
BAX' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.47
Current: 0.33

0.22
0.47
Interest Coverage 17.21
BAX's Interest Coverage is ranked higher than
64% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. BAX: 17.21 )
BAX' s 10-Year Interest Coverage Range
Min: 3.8   Max: 32.02
Current: 17.21

3.8
32.02
F-Score: 5
Z-Score: 3.22
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.81
BAX's Operating margin (%) is ranked higher than
86% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. BAX: 14.81 )
BAX' s 10-Year Operating margin (%) Range
Min: 6.37   Max: 22.9
Current: 14.81

6.37
22.9
Net-margin (%) 11.14
BAX's Net-margin (%) is ranked higher than
85% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.97 vs. BAX: 11.14 )
BAX' s 10-Year Net-margin (%) Range
Min: 4.08   Max: 17.55
Current: 11.14

4.08
17.55
ROE (%) 22.29
BAX's ROE (%) is ranked higher than
94% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.15 vs. BAX: 22.29 )
BAX' s 10-Year ROE (%) Range
Min: 11.04   Max: 34.4
Current: 22.29

11.04
34.4
ROA (%) 7.33
BAX's ROA (%) is ranked higher than
84% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. BAX: 7.33 )
BAX' s 10-Year ROA (%) Range
Min: 2.78   Max: 13.46
Current: 7.33

2.78
13.46
ROC (Joel Greenblatt) (%) 22.99
BAX's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. BAX: 22.99 )
BAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.24   Max: 72.39
Current: 22.99

11.24
72.39
Revenue Growth (%) 8.70
BAX's Revenue Growth (%) is ranked higher than
82% of the 261 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. BAX: 8.70 )
BAX' s 10-Year Revenue Growth (%) Range
Min: -13.2   Max: 17.3
Current: 8.7

-13.2
17.3
EBITDA Growth (%) 12.30
BAX's EBITDA Growth (%) is ranked higher than
83% of the 219 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. BAX: 12.30 )
BAX' s 10-Year EBITDA Growth (%) Range
Min: -12.1   Max: 33
Current: 12.3

-12.1
33
EPS Growth (%) 15.30
BAX's EPS Growth (%) is ranked higher than
83% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. BAX: 15.30 )
BAX' s 10-Year EPS Growth (%) Range
Min: -17.1   Max: 61.5
Current: 15.3

-17.1
61.5
» BAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BAX Guru Trades in Q4 2013

Scott Black 158,392 sh (+776.11%)
John Rogers 61,251 sh (+24.31%)
Robert Olstein 77,000 sh (+24.19%)
Bill Frels 2,155,658 sh (+22.89%)
Jeff Auxier 25,981 sh (+13.05%)
Jeremy Grantham 2,919,918 sh (+7.78%)
John Buckingham 98,705 sh (+0.56%)
Murray Stahl 4,272 sh (unchged)
Chris Davis 5,495 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Bill Nygren 1,523,000 sh (unchged)
Dodge & Cox 3,382 sh (unchged)
James Barrow Sold Out
Steven Cohen Sold Out
Pioneer Investments Sold Out
Tweedy Browne 2,601,953 sh (-0.07%)
Diamond Hill Capital 1,654,045 sh (-3.16%)
Mario Gabelli 227,850 sh (-5.42%)
Manning & Napier Advisors, Inc 228,450 sh (-10.85%)
Vanguard Health Care Fund 2,410,000 sh (-24.2%)
Ray Dalio 188,663 sh (-24.85%)
Jim Simons 951,600 sh (-47.51%)
Paul Tudor Jones 5,600 sh (-56.59%)
John Hussman 107,450 sh (-58.26%)
Jean-Marie Eveillard 7,600 sh (-99.44%)
» More
Q1 2014

BAX Guru Trades in Q1 2014

David Dreman 2,453 sh (New)
Charles Brandes 204,560 sh (New)
Steven Cohen 256,874 sh (New)
Jeremy Grantham 3,521,356 sh (+20.6%)
Paul Tudor Jones 6,400 sh (+14.29%)
Scott Black 179,629 sh (+13.41%)
Bill Frels 2,342,265 sh (+8.66%)
Diamond Hill Capital 1,769,316 sh (+6.97%)
Bill Nygren 1,623,000 sh (+6.57%)
John Buckingham 100,126 sh (+1.44%)
Dodge & Cox 3,404 sh (+0.65%)
Jeff Auxier 25,981 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Rogers 61,251 sh (unchged)
Tweedy Browne 2,601,848 sh (unchged)
Murray Stahl 4,272 sh (unchged)
Chris Davis Sold Out
Mario Gabelli 225,500 sh (-1.03%)
Manning & Napier Advisors, Inc 216,402 sh (-5.27%)
Robert Olstein 68,000 sh (-11.69%)
Jim Simons 812,400 sh (-14.63%)
Ray Dalio 62,263 sh (-67%)
Signature Select Canadian Fund 103,600 sh (-75.82%)
Vanguard Health Care Fund 531,100 sh (-77.96%)
Jean-Marie Eveillard 1,100 sh (-85.53%)
John Hussman 7,450 sh (-93.07%)
» More
Q2 2014

BAX Guru Trades in Q2 2014

John Keeley 37,150 sh (New)
Jean-Marie Eveillard 1,000,696 sh (+90872.4%)
Paul Tudor Jones 15,503 sh (+142.23%)
Murray Stahl 9,722 sh (+127.57%)
Jim Simons 1,184,600 sh (+45.81%)
Mario Gabelli 243,400 sh (+7.94%)
Charles Brandes 209,907 sh (+2.61%)
John Buckingham 101,227 sh (+1.1%)
Manning & Napier Advisors, Inc 218,691 sh (+1.06%)
Bill Frels 2,342,897 sh (+0.03%)
John Rogers 61,251 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Bill Nygren 1,623,000 sh (unchged)
David Dreman Sold Out
Vanguard Health Care Fund Sold Out
Tweedy Browne 2,592,155 sh (-0.37%)
Dodge & Cox 3,382 sh (-0.65%)
Jeff Auxier 25,331 sh (-2.5%)
Jeremy Grantham 3,397,750 sh (-3.51%)
Diamond Hill Capital 1,635,153 sh (-7.58%)
Robert Olstein 60,000 sh (-11.76%)
Scott Black 123,976 sh (-30.98%)
John Hussman 3,725 sh (-50%)
Ray Dalio 5,763 sh (-90.74%)
» More
Q3 2014

BAX Guru Trades in Q3 2014

David Dreman 3,397 sh (New)
Ray Dalio 18,463 sh (+220.37%)
John Keeley 40,650 sh (+9.42%)
Charles Brandes 225,023 sh (+7.2%)
John Rogers 63,051 sh (+2.94%)
Diamond Hill Capital 1,676,366 sh (+2.52%)
Manning & Napier Advisors, Inc 222,126 sh (+1.57%)
John Buckingham 101,959 sh (+0.72%)
Scott Black 124,346 sh (+0.3%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Bill Nygren 1,623,000 sh (unchged)
Murray Stahl 9,722 sh (unchged)
Dodge & Cox 3,382 sh (unchged)
John Hussman 3,725 sh (unchged)
Robert Olstein Sold Out
Bill Frels 2,336,628 sh (-0.27%)
Jean-Marie Eveillard 997,056 sh (-0.36%)
Jeff Auxier 25,231 sh (-0.39%)
Tweedy Browne 2,581,277 sh (-0.42%)
Jeremy Grantham 3,253,150 sh (-4.26%)
Mario Gabelli 224,940 sh (-7.58%)
Paul Tudor Jones 9,539 sh (-38.47%)
Jim Simons 649,700 sh (-45.15%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Robert Olstein 2014-09-30 Sold Out 0.59%$71.28 - $77 $ 72.4-3%0
David Dreman 2014-09-30 New Buy0.02%$71.28 - $77 $ 72.4-3%3397
Ray Dalio 2014-09-30 Add 220.37%0.01%$71.28 - $77 $ 72.4-3%18463
Scott Black 2014-06-30 Reduce -30.98%0.43%$71.98 - $75.45 $ 72.4-2%123976
Jean-Marie Eveillard 2014-06-30 Add 90872.4%0.18%$71.98 - $75.45 $ 72.4-2%1000696
Vanguard Health Care Fund 2014-06-30 Sold Out 0.11%$71.98 - $75.45 $ 72.4-2%0
John Keeley 2014-06-30 New Buy0.05%$71.98 - $75.45 $ 72.4-2%37150
Ray Dalio 2014-06-30 Reduce -90.74%0.03%$71.98 - $75.45 $ 72.4-2%5763
John Hussman 2014-06-30 Reduce -50%0.02%$71.98 - $75.45 $ 72.4-2%3725
David Dreman 2014-06-30 Sold Out 0.01%$71.98 - $75.45 $ 72.4-2%0
John Hussman 2014-03-31 Reduce -93.07%0.49%$66.49 - $72.85 $ 72.45%7450
Vanguard Health Care Fund 2014-03-31 Reduce -77.96%0.41%$66.49 - $72.85 $ 72.45%531100
Charles Brandes 2014-03-31 New Buy0.19%$66.49 - $72.85 $ 72.45%204560
Scott Black 2014-03-31 Add 13.41%0.17%$66.49 - $72.85 $ 72.45%179629
Ray Dalio 2014-03-31 Reduce -67%0.07%$66.49 - $72.85 $ 72.45%62263
David Dreman 2014-03-31 New Buy0.01%$66.49 - $72.85 $ 72.45%2453
Jean-Marie Eveillard 2014-03-31 Reduce -85.53%$66.49 - $72.85 $ 72.45%1100
Chris Davis 2014-03-31 Sold Out $66.49 - $72.85 $ 72.45%0
Scott Black 2013-12-31 Add 776.11%1.06%$63.89 - $69.47 $ 72.48%158392
John Hussman 2013-12-31 Reduce -58.26%0.54%$63.89 - $69.47 $ 72.48%107450
Jean-Marie Eveillard 2013-12-31 Reduce -99.44%0.26%$63.89 - $69.47 $ 72.48%7600
James Barrow 2013-12-31 Sold Out 0.22%$63.89 - $69.47 $ 72.48%0
Vanguard Health Care Fund 2013-12-31 Reduce -24.2%0.17%$63.89 - $69.47 $ 72.48%2410000
Robert Olstein 2013-12-31 Add 24.19%0.15%$63.89 - $69.47 $ 72.48%77000
Ray Dalio 2013-12-31 Reduce -24.85%0.03%$63.89 - $69.47 $ 72.48%188663
John Rogers 2013-12-31 Add 24.31%0.01%$63.89 - $69.47 $ 72.48%61251
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Baxter International Inc

Diamond Hill Capital Comments on Baxter International Inc - Jul 25, 2014

We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Baxter International - Jan 15, 2014

Baxter International, Inc. (BAX), a medical supply manufacturer, declined during the quarter due to concerns that it could lose more market share than expected in the hemophilia market. 

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Baxter International Inc

Diamond Hill Capital Comments on Baxter International Inc
We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position. Read more...
Diamond Hill Capital Comments on Baxter International
Baxter International, Inc. (BAX), a medical supply manufacturer, declined during the quarter due to concerns that it could lose more market share than expected in the hemophilia market.  Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.20
BAX's P/E(ttm) is ranked higher than
88% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.50 vs. BAX: 21.20 )
BAX' s 10-Year P/E(ttm) Range
Min: 12.15   Max: 57.43
Current: 21.2

12.15
57.43
P/B 4.70
BAX's P/B is ranked higher than
63% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. BAX: 4.70 )
BAX' s 10-Year P/B Range
Min: 3.78   Max: 6.39
Current: 4.7

3.78
6.39
P/S 2.40
BAX's P/S is ranked higher than
73% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.92 vs. BAX: 2.40 )
BAX' s 10-Year P/S Range
Min: 1.82   Max: 3.88
Current: 2.4

1.82
3.88
PFCF 29.60
BAX's PFCF is ranked higher than
85% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 719.57 vs. BAX: 29.60 )
BAX' s 10-Year PFCF Range
Min: 13.01   Max: 30.49
Current: 29.6

13.01
30.49
EV-to-EBIT 18.25
BAX's EV-to-EBIT is ranked higher than
85% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.27 vs. BAX: 18.25 )
BAX' s 10-Year EV-to-EBIT Range
Min: 10   Max: 42.4
Current: 18.25

10
42.4
PEG 3.29
BAX's PEG is ranked higher than
88% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BAX: 3.29 )
BAX' s 10-Year PEG Range
Min: 0.67   Max: 343.82
Current: 3.29

0.67
343.82
Shiller P/E 19.20
BAX's Shiller P/E is ranked higher than
94% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 398.57 vs. BAX: 19.20 )
BAX' s 10-Year Shiller P/E Range
Min: 14.67   Max: 36.58
Current: 19.2

14.67
36.58
Current Ratio 1.61
BAX's Current Ratio is ranked higher than
53% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. BAX: 1.61 )
BAX' s 10-Year Current Ratio Range
Min: 1.08   Max: 2.7
Current: 1.61

1.08
2.7
Quick Ratio 0.99
BAX's Quick Ratio is ranked higher than
51% of the 275 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. BAX: 0.99 )
BAX' s 10-Year Quick Ratio Range
Min: 0.74   Max: 2.02
Current: 0.99

0.74
2.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.80
BAX's Dividend Yield is ranked higher than
82% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.34 vs. BAX: 2.80 )
BAX' s 10-Year Dividend Yield Range
Min: 1.13   Max: 3
Current: 2.8

1.13
3
Dividend Payout 0.60
BAX's Dividend Payout is ranked higher than
85% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BAX: 0.60 )
BAX' s 10-Year Dividend Payout Range
Min: 0.26   Max: 3.4
Current: 0.6

0.26
3.4
Dividend growth (3y) 17.60
BAX's Dividend growth (3y) is ranked higher than
86% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.40 vs. BAX: 17.60 )
BAX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.5
Current: 17.6

0
22.5
Yield on cost (5-Year) 5.81
BAX's Yield on cost (5-Year) is ranked higher than
92% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. BAX: 5.81 )
BAX' s 10-Year Yield on cost (5-Year) Range
Min: 2.34   Max: 6.22
Current: 5.81

2.34
6.22
Share Buyback Rate 2.60
BAX's Share Buyback Rate is ranked higher than
93% of the 239 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. BAX: 2.60 )
BAX' s 10-Year Share Buyback Rate Range
Min: 7.7   Max: -10.6
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 17.84
BAX's Price/Tangible Book is ranked higher than
60% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.41 vs. BAX: 17.84 )
BAX' s 10-Year Price/Tangible Book Range
Min: 3.91   Max: 27.72
Current: 17.84

3.91
27.72
Price/DCF (Projected) 1.44
BAX's Price/DCF (Projected) is ranked higher than
87% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. BAX: 1.44 )
BAX' s 10-Year Price/DCF (Projected) Range
Min: 1.02   Max: 4.98
Current: 1.44

1.02
4.98
Price/Median PS Value 0.95
BAX's Price/Median PS Value is ranked higher than
85% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.20 vs. BAX: 0.95 )
BAX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.56
Current: 0.95

0.3
2.56
Price/Peter Lynch Fair Value 3.04
BAX's Price/Peter Lynch Fair Value is ranked higher than
89% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BAX: 3.04 )
BAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.74   Max: 8.11
Current: 3.04

0.74
8.11
Price/Graham Number 4.10
BAX's Price/Graham Number is ranked higher than
76% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.72 vs. BAX: 4.10 )
BAX' s 10-Year Price/Graham Number Range
Min: 1.65   Max: 6.71
Current: 4.1

1.65
6.71
Earnings Yield (Greenblatt) 5.50
BAX's Earnings Yield (Greenblatt) is ranked higher than
85% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. BAX: 5.50 )
BAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.4   Max: 10
Current: 5.5

2.4
10
Forward Rate of Return (Yacktman) 10.81
BAX's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. BAX: 10.81 )
BAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.6   Max: 25.4
Current: 10.81

0.6
25.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, COV, TMO, COO, ISRG » details
Traded in other countries:BAX.Switzerland, BTL.Germany, 0QK8.UK, BAX.Mexico
Baxter International Inc is a Delaware corporation incorporated in 1931. The Company is a healthcare company engaged in the development, manufacture and sale of products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely BioScience and Medical Products. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as bio surgery products; and vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies. The business manufactures solutions and other products for peritoneal dialysis, a home-based therapy, and also distributes products for hemodialysis, which is generally conducted in a hospital or clinic. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The BioScience segment faces competitors from pharmaceutical, biotechnology and other companies. The Medical Products segment faces competition from medical device manufacturers and pharmaceutical companies. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.
» More Articles for BAX

Headlines

Articles On GuruFocus.com
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Abbott: A Brighter Future Aug 28 2014 
Diamond Hill Capital Comments on Baxter International Inc Jul 25 2014 
Why I Bought Baxter International Jun 19 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
Two Stocks On My Watch List For June 2014 May 29 2014 
Companies That Are Raising Dividends May 16 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 

More From Our Partners
NxStage Medical Unveils Streamline Express Dialyzer - Analyst Blog Nov 21 2014 - ZACKS

More From Other Websites
Finding a Margin of Safety in a Fully Valued Market Nov 21 2014
Merrimack Pharmaceuticals' MM-398 Gets Fast Track Status Nov 20 2014
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine... Nov 19 2014
Baxter to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 13 2014
Baxter to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 13 2014
Baxter Declares Quarterly Dividend Nov 11 2014
Baxter Declares Quarterly Dividend Nov 11 2014
Nektar Therapeutics Beats on Q3 Earnings and Revenues Nov 10 2014
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer Nov 06 2014
'Mad Money' Lightning Round: Pull the Trigger on Baxter Nov 06 2014
The Thorns, Roses, All Time Highs, and ETF All Time Highs... Nov 05 2014
Baxter to Present at the Stifel 2014 Healthcare Conference Nov 05 2014
Baxter to Present at the Stifel 2014 Healthcare Conference Nov 05 2014
BAXTER INTERNATIONAL INC Financials Nov 05 2014
Seven Obamacare Bills That The New GOP Senate Majority Should Pass In 2015 Nov 05 2014
10-Q for Baxter International, Inc. Oct 31 2014
Baxter’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability... Oct 30 2014
Baxter’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability... Oct 30 2014
BAXTER INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Oct 29 2014
Baxter International Gets FDA Nod for Hemophilia A Drug Oct 27 2014
UPDATE 1-Baxter's blood disorder drug gets FDA approval (Oct 24) Oct 27 2014
FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired... Oct 24 2014
Baxter's blood disorder drug gets FDA approval Oct 24 2014
FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired... Oct 24 2014
AstraZeneca cancer drug pipeline gets boost from European green light Oct 24 2014
AstraZeneca cancer drug pipeline gets boost from European green light Oct 24 2014
AstraZeneca cancer drug pipeline gets boost from European green light Oct 24 2014
Stock pickers shopping list Oct 23 2014
Baxter to Present at the 2014 Credit Suisse Healthcare Conference Oct 22 2014
Baxter to Present at the 2014 Credit Suisse Healthcare Conference Oct 22 2014
Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency Oct 20 2014
Baxter’s Third Quarter Financial Results Exceed Guidance Oct 16 2014
Baxter meets 3Q profit forecasts Oct 16 2014
PharmaEngine and Merrimack Amend MM-398 License Agreement Sep 26 2014
Merrimack, Baxter to collaborate on cancer drug Sep 24 2014
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and... Sep 24 2014
Health care company expanding in Alabama Aug 20 2014
Baxter Opens Its First State-of-the-Art Biologics Facility in Asia, Announces Expansion Plans with... Aug 07 2014
Pfizer buying two Baxter vaccines for $635M Jul 30 2014
Baxter Highlights Commitment to Innovation and Focus on Improving Patient Outcomes at WFH World... May 12 2014
Baxter splitting into 2 separate businesses Mar 27 2014
Baxter Announces Plans to Create Two Separate Leading Global Healthcare Companies Mar 27 2014
Exclusive - Baxter explores sale of its vaccines business: sources Mar 26 2014
Danone could spend Medical Nutrition cash on baby food, dairy deals Mar 07 2014
Baxter to Present at Barclay’s Global Healthcare Conference Feb 27 2014
Baxter Presents Data at EAHAD from Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment... Feb 27 2014
Fresenius eyes bid for Danone tube feeding products arm - sources Feb 19 2014
Baxter Declares Quarterly Dividend Feb 18 2014
Baxter to Present at Cowen & Company’s 34th Annual Health Care Conference Feb 13 2014
Baxter to Present at Upcoming Global Healthcare Conferences Feb 10 2014
Shri Ghulam Nabi Azad Inaugurates Baxter Global Research Center at Syngene... Feb 05 2014
Baxter Announces Restructured Agreement with Xenetic Biosciences, Further Bolstering Its Broad... Jan 30 2014
Dow closes above 15,000 for first time May 07 2013

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK